Interferon receptor 1 antibodies and their uses
View Patent ↗The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
1. An isolated monoclonal antibody, or antigen-binding portion thereof, which specifically binds to human interferon alpha receptor 1 (IFNAR-1), wherein the antibody or antigen-binding portion thereof is selected from the group consisting of:
(a) an antibody, or antigen-binding portion thereof, comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 1; a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5; a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9; a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 13; a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 17; and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:21;
(b) an antibody, or antigen-binding portion thereof, comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:2; a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:6; a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 10; a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 14; a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 18; and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:22; and
(c) an antibody, or antigen-binding portion thereof, comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4; a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8; a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 12; a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 16; a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:20; and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:24.
2. An isolated monoclonal antibody, or antigen-binding portion thereof, which specifically binds to human interferon alpha receptor 1 (IFNAR-1), wherein the antibody or antigen-binding portion thereof is selected from the group consisting of:
(a) an antibody, or antigen-binding portion thereof, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:25 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:29;
(b) an antibody, or antigen-binding portion thereof, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:26 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:30; and
(c) an antibody, or antigen-binding portion thereof, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:28 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:32.
3. A composition comprising the antibody, or antigen-binding portion thereof, of claim 1 , and a pharmaceutically acceptable carrier.
4. An immunoconjugate comprising the antibody, or antigen-binding portion thereof, of claim 1 , linked to a therapeutic agent.
5. The immunoconjugate of claim 4 , further comprising a pharmaceutically acceptable carrier.
6. The immunoconjugate of claim 4 , wherein the therapeutic agent is a cytotoxin or a radioactive isotope.
7. A method for preparing an anti-IFNAR-1 antibody comprising:
(a) providing: (i) a heavy chain variable region antibody sequence comprising a CDR1 sequence that is selected from the group consisting of SEQ ID NOs: 1, 2, and 4, a CDR2 sequence that is selected from the group consisting of SEQ ID NOs: 5, 6, and 8; and a CDR3 sequence that is selected from the group consisting of SEQ ID NOs: 9, 10, and 12; or (ii) a light chain variable region antibody sequence comprising a CDR1 sequence that is selected from the group consisting of SEQ ID NOs: 13, 14, and 16, a CDR2 sequence that is selected from the group consisting of SEQ ID NOs: 17, 18, and 20 and a CDR3 sequence that is selected from the group consisting of SEQ ID NOs: 21, 22, and 24;
(b) altering at least one amino acid residue within at least one variable region antibody sequence, said sequence being selected from the heavy chain variable region antibody sequence and the light chain variable region antibody sequence, to create at least one altered antibody sequence; and
(c) expressing the altered antibody sequence as a protein.
8. An isolated nucleic acid encoding a heavy chain variable region and a light chain variable region of an anti-IFNAR-1 antibody, or antigen-binding portion thereof, said variable regions comprising:
(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:25; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:29;
(b) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:26; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:30; or
(c) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:28; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:32.
9. An isolated nucleic acid encoding a heavy chain variable region of an anti-IFNAR-1 monoclonal antibody, or antigen-binding portion thereof, comprising amino acids having the sequence set forth in SEQ ID NO:25, SEQ ID NO:26, or SEQ ID NO:28.
10. An isolated nucleic acid encoding a light chain variable region of an anti-IFNAR-1 monoclonal antibody, or antigen-binding portion thereof, comprising amino acids having the sequence set forth in SEQ ID NO:29, SEQ ID NO:30, or SEQ ID NO:32.
11. An isolated nucleic acid encoding a heavy chain variable region of an anti-IFNAR-1 monoclonal antibody, or antigen-binding portion thereof, said nucleic acid comprising nucleotides having the sequence set forth in SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35 or SEQ ID NO:36.
12. An isolated nucleic acid encoding a light chain variable region of an anti-IFNAR-1 monoclonal antibody, or antigen-binding portion thereof, said nucleic acid comprising nucleotides having the sequence set forth in SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:40.
13. An expression vector comprising the nucleic acid of claim 8 .
14. A host cell expressing a polypeptide encoded by the nucleic acid of claim 8 .
15. A transgenic mouse comprising the host cell of claim 14 , wherein the mouse expresses a polypeptide encoded by the nucleic acid.